Photo taken from CCTG/X
Aug 12, 2024, 01:27
Michael Ong received $2.4M for metastatic prostate cancer – CCTG
The Canadian Cancer Trials Group shared on X:
“Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from CIHR to support the CCTG PR26 (TRIPLE-SWITCH) trial. The study aims to personalize chemotherapy use and improve survival for patients with metastatic prostate cancer.”